The DOI matches its Crossref record.
Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 Patients
Abstract
OBJECTIVE: To evaluate the efficacy of octreotide in the treatment of pituitary thyroid-stimulating hormone (TSH)-secreting adenomas. DATA SOURCES: Combination of review and original data. Review data included information supplied by Sandoz Pharmaceuticals from patient case report forms and information from abstracts and articles published in the French or English language between 1987 and 1991. Original data included follow-up data on 15 of 37 previously reported cases and data on 15 new cases provided by 11 investigators. STUDY SELECTION: Fifty-two cases from 24 medical centers in nine countries reported between 1987 and 1991. DATA EXTRACTION: Chief clinical characteristics of the patients; dose and duration of octreotide treatment; serum TSH, thyroid hormone, and free alpha-subunit levels before and during treatment; serial anatomic evaluation of the pituitary gland by either computed tomographic scanning or magnetic resonance imaging; and side effects. DATA SYNTHESIS: After the first octreotide dose (50 to 100 micrograms), TSH levels decreased in all but 2 patients (mean decrease for the whole group, 55.8% +/- 27%). Levels of alpha-subunit decreased in 15 of the 19 patients who had alpha-subunit assessments (mean decrease, 37.5% +/- 24%). Reduction of TSH levels after short-term treatment (50 or 100 micrograms two or three times daily) was observed in 30 to 33 patients (mean decrease, 74.1%). Thyroid hormone levels were reduced in all patients and returned to normal in 73%. Despite an initial response to therapy, thyroid hormone levels continued to rise ("true escape") in 2 patients receiving short-term therapy and in 3 patients receiving long-term therapy. Partial shrinkage of the adenoma occurred in 11 patients. CONCLUSIONS: Octreotide is an effective treatment for TSH-secreting adenomas. Thyroid-stimulating hormone levels almost always decreased, and thyroid hormone levels reverted to normal in about three quarters of patients. Partial tumor shrinkage was observed in one third of patients receiving long-term octreotide treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Brücker-Davis, F., Oldfield, E. H., Skarulis, M. C., Doppman, J. L., & Weintraub, B. D. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.2.476 · Cited by 311
Self-citationThe changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients
Socin, H., Chanson, P., Delemer, B., Tabarin, A., Rohmer, V, Mockel, J., Stevenaert, A., & Beckers, A. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480433 · Cited by 274
Self-citation
Metadata
- Authors
- Chanson, P., Weintraub, B. D., & Harris, A. G.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1993-08-01
- Volume
- 119
- Issue
- 3
- Pages
- 236-240
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1989522103
- Cited by
- 212
- References
- 0
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 Patients. https://app.cochat.ai/papers/10.7326/0003-4819-119-3-199308010-00010
- The paper
- Chanson, P., Weintraub, B. D., & Harris, A. G. (1993). Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 Patients. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-119-3-199308010-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.